Pfizer Receives FDA Approval for Elrexfio Cancer Drug

1 Mins read

Pfizer, the renowned New York-based drugmaker, has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for its ground-breaking medication, Elrexfio. This drug is specifically designed to treat adults suffering from relapsed or refractory multiple myeloma, an incurable blood cancer.

Elrexfio stands out as the first ready-to-use, fixed-dose subcutaneous BCMA-directed agent available in the United States. With its once-every-other-week dosage for responsive patients, following an initial 24 weeks of weekly therapy, Pfizer aims to establish Elrexfio as the next standard of care for multiple myeloma. The drug’s impressive clinical results, combined with its convenient subcutaneous administration, offer promising prospects for patients.

Having successfully obtained FDA priority review for Elrexfio in February, Pfizer has demonstrated its commitment to bringing advanced treatment options to patients with serious diseases. This designation significantly shortens the review period and emphasizes the therapeutic potential of the medication.

Pfizer is dedicated to expanding the clinical program of Elrexfio, exploring its use in earlier lines of treatment for multiple myeloma. The company aims to evaluate the drug both as a monotherapy and in combination with standard or novel therapies.

With more than 176,000 new cases diagnosed globally every year, including 35,000 cases in the United States alone, multiple myeloma ranks as the second most common blood cancer. Analyst Akash Tewari from Jefferies estimates that by 2030, Elrexfio’s sales could reach an impressive $1 billion. The approval of this medication brings newfound hope to patients battling this devastating disease.

Related posts

Banking Regulations for Preventing Failures

2 Mins read
Banking regulators have the power to prevent future bank collapses, according to a panel of banking experts who emphasized the importance of…

Dave's Strong Q4 Performance

1 Mins read
Shares of Dave surged on Tuesday following the digital bank’s announcement of a profitable fourth quarter earlier than expected, with a positive…

DaVita Expands in Latin America

1 Mins read
Shares of DaVita reached record levels as the kidney care services company announced its significant expansion into Latin America through a $300…

Leave a Reply

Your email address will not be published. Required fields are marked *

29 − 27 =